Administration of STZ caused rapid destruction of pancreatic β-cells in rats, which led to impaired glucose stimulated insulin release and insulin resistance, both of which are marked feature of type II diabetes.[20] Oral hypoglycemic agents and insulin are currently available for treating DM. The gene discussed is INS; the disease is diabetes mellitus.